Advertisement

Proton Beam Therapy for Locally Recurrent Parotid Gland Cancer

  • Yusuke Azami
  • Yuichiro HayashiEmail author
  • Tatsuya Nakamura
  • Kanako Kimura
  • Hisashi Yamaguchi
  • Takashi Ono
  • Kanako Takayama
  • Katsumi Hirose
  • Tomonori Yabuuchi
  • Motohisa Suzuki
  • Yoshiomi Hatayama
  • Masato Hareyama
  • Yasuhiro Kikuchi
  • Nobukazu Fuwa
Original Article
  • 85 Downloads

Abstract

The aim of this study was to evaluate the efficacy and safety of proton beam therapy for patients with locally recurrent parotid cancer. Between 2009 and 2012, ten patients with locally recurrent parotid gland cancer were treated with proton beam therapy (70.2 Gy equivalents in 32 fractions) with or without intra-arterial infusion chemotherapy of cisplatin (50 mg/body/week, for a total of 5–8 weeks). The median follow-up was 24 months (range 10–49 months). The 1-year overall survival and local control rates were 80 %, and the 3-year overall survival and local control rates were 60 %. None of the patients experienced grade 3–5 toxicities in the treatment or the follow-up periods. These findings suggest that proton beam therapy could be applied effectively and safely for patients with locally recurrent parotid gland cancer.

Keywords

Intra-arterial chemotherapy Local recurrence Parotid gland cancer Proton beam therapy Re-irradiation 

Notes

Compliance with Ethical Standards

Conflict of interest

All authors have no conflicts of interest to declare.

Informed Consent

This study is a retrospective study. Therefore, this type of study formal consent is not required.

Human and Animal Rights

This article does not contain any studies with animals performed by any of the authors.

References

  1. 1.
    Armstrong JG, Harrison LB, Spiro RH, Fass DE, Strong EW, Fuks ZY (1990) Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy. Arch Otolaryngol Head Neck Surg 116:290–293CrossRefGoogle Scholar
  2. 2.
    Bell RB, Dierks EJ, Homer L, Potter BE (2005) Management and outcome of patients with malignant salivary gland tumors. J Oral Maxillofac Surg 63:917–928CrossRefGoogle Scholar
  3. 3.
    Surakanti SG, Agulnik M (2008) Salivary gland malignancies: the role for chemotherapy and molecular targeted agents. Semin Oncol 35:309–319CrossRefGoogle Scholar
  4. 4.
    Fuwa N, Ito Y, Matsumoto A et al (2000) A combination therapy of continuous superselective intraarterial carboplatin infusion and radiation therapy for locally advanced head and neck carcinoma. Phase 1 study. Cancer 89:2099–2105CrossRefGoogle Scholar
  5. 5.
    Nakamura T, Fuwa N, Takayama K et al (2011) A new method using MRI to delineate areas of head and neck cancer targeted by intra-arterial infusion via a superficial temporal artery. Oral Oncol 47:387–390CrossRefGoogle Scholar
  6. 6.
    Theresa AG, David WE, Vivian W (2005) Adenoid cystic carcinoma of the major salivary glands treated with surgery and radiation. The Laryngoscope 115:1278–1282CrossRefGoogle Scholar
  7. 7.
    Garden AS, Weber RS, Morrison WH, Ang KK, Peters LJ (1995) The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Radiat Oncol Biol Phys 32(3):619–626CrossRefGoogle Scholar
  8. 8.
    Pederson A, Salama J, Haraf D, Witt M, Stenson K, Vokes E, et al (2008) Chemoradiotherapy for locoregionally advanced and high risk salivary gland malignancies. In: Wolf GT, Weymuller EA, Myers J (eds) Poster session presented at: 7th international conference on head and neck cancer. 2008 Jul 19–23, The American Head and Neck Society, San FranciscoGoogle Scholar
  9. 9.
    Nakamura T, Kodaira T, Tachibana H et al (2008) Chemoradiotherapy for locally recurrent nasopharyngeal carcinoma: treatment outcome and prognostic factors. Jpn J Clin Oncol 38:803–809CrossRefGoogle Scholar
  10. 10.
    Frank SJ, Selek U (2010) Proton beam therapy for head and neck malignancies. Curr Oncol Rep 12:202–207CrossRefGoogle Scholar
  11. 11.
    Fokas E, Kraft G, An H et al (2009) Ion beam radiobiology and cancer: time to update ourselves. Biochim Biophys Acta 1796(2):216–229PubMedGoogle Scholar
  12. 12.
    Tohnai I, Fuwa N, Hayashi Y et al (1998) New superselective intra-arterial infusion via superficial temporal artery for cancer of the tongue and tumor tissue platinum concentration after carboplatin (CBDCA) infusion. Oral Oncol 34:387–390CrossRefGoogle Scholar
  13. 13.
    Mitsudo K, Koizumi T, Iida M et al (2014) Retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy for stage III and IV oral cancer: analysis of therapeutic results in 112 cases. Radiother Oncol 111:306–310CrossRefGoogle Scholar
  14. 14.
    Mitsudo K, Shigetomi T, Fujimoto Y et al (2011) Organ preservation with daily concurrent chemoradiotherapy using superselective intra-arterial infusion via a superficial temporal artery for T3 and T4 head and neck cancer. Int J Radiat Oncol Biol Phys 79:1428–1435CrossRefGoogle Scholar
  15. 15.
    Teo PM, Chan AT, Lee WY et al (2000) Failure patterns and factors affecting prognosis of salivary gland carcinoma: retrospective study. Hong Kong Med J 6:29–36PubMedGoogle Scholar

Copyright information

© Association of Otolaryngologists of India 2016

Authors and Affiliations

  • Yusuke Azami
    • 1
  • Yuichiro Hayashi
    • 1
    • 2
    Email author
  • Tatsuya Nakamura
    • 1
  • Kanako Kimura
    • 1
  • Hisashi Yamaguchi
    • 1
  • Takashi Ono
    • 1
  • Kanako Takayama
    • 2
  • Katsumi Hirose
    • 1
  • Tomonori Yabuuchi
    • 1
  • Motohisa Suzuki
    • 1
  • Yoshiomi Hatayama
    • 1
  • Masato Hareyama
    • 1
  • Yasuhiro Kikuchi
    • 1
  • Nobukazu Fuwa
    • 3
  1. 1.Department of Radiation OncologySouthern Tohoku Proton Therapy CenterKoriyama CityJapan
  2. 2.Department of Oral and Maxillofacial SurgeryYokohama City University Graduate School of MedicineYokohamaJapan
  3. 3.Department of Radiation OncologyHyogo Ion Beam Medical CenterTatsunoJapan

Personalised recommendations